Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4045 Target Snapshot

5'-AMP-activated protein kinase catalytic subunit alpha-1 · SINGLE PROTEIN · Homo sapiens

1,939Compounds
294Assays
12Approved Drugs
1,402.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q13131. Use UniProt Q13131 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q13131 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5'-AMP-activated protein kinase catalytic subunit alpha-1 as ChEMBL target CHEMBL4045, mapped to UniProt Q13131. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5'-AMP-activated protein kinase catalytic subunit alpha-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4045
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13131
5'-AMP-activated protein kinase catalytic subunit alpha-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5'-AMP-activated protein kinase catalytic subunit alpha-1 is the right protein anchor across sources, using UniProt Q13131 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5'-AMP-activated protein kinase catalytic subunit alpha-1
UniProt AccessionQ13131
Component TypeProtein
Sequence Length559 aa

5'-AMP-activated protein kinase catalytic subunit alpha-1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as 5'-AMP-activated protein kinase catalytic subunit alpha-1, mapped to UniProt Q13131. Sequence length is 559 aa.

Mapped IDQ13131
Review name5'-AMP-activated protein kinase catalytic subunit alpha-1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

12
Approved
6
Phase III
15
Phase II
14
Phase I
Assay Mix

Activity Type Distribution

IC5063.0
KI929.0
EC5022.0
KD388.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1980995 9.5 Ki 0.3162 Preclinical
CHEMBL1967878 9.0 Ki 1.0 Clinical
CHEMBL4110683 8.92 EC50 1.2 Preclinical
CHEMBL4580220 8.85 IC50 1.4 Preclinical
CHEMBL1980407 8.5 Ki 3.162 Preclinical
CHEMBL388978 8.43 Kd 3.7 Preclinical
CHEMBL1973540 8.4 Ki 3.981 Preclinical
CHEMBL1969588 8.4 Ki 3.981 Preclinical
CHEMBL1997924 8.4 Ki 3.981 Preclinical
CHEMBL3780091 8.26 IC50 5.5 Preclinical
Distribution

pChEMBL Value Distribution

27
5.0
123
5.5
104
6.0
81
6.5
34
7.0
22
7.5
16
8.0
3
8.5
1
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

ENTRECTINIB
CHEMBL1983268
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
PALBOCICLIB
CHEMBL189963
Approved 2015
NINTEDANIB
CHEMBL502835
Approved 2014
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

294
Total Assays
300
Tested Compounds
2
Assay Types
Binding — 291 assays, 111 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 197 81 6.6
cell-based format 38 2 6.1
subcellular format 36 27 6.0
assay format 20 1 5.1
Functional — 3 assays, 300 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 299 6.1
cell-based format 1 1 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine